NEXTBio Capital Management LP Makes New Investment in Zenas BioPharma, Inc. $ZBIO

NEXTBio Capital Management LP acquired a new position in Zenas BioPharma, Inc. (NASDAQ:ZBIO) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 321,983 shares of the company’s stock, valued at approximately $11,691,000. Zenas BioPharma accounts for about 6.9% of NEXTBio Capital Management LP’s portfolio, making the stock its 4th largest position.

Several other hedge funds have also added to or reduced their stakes in ZBIO. Federated Hermes Inc. raised its position in Zenas BioPharma by 45.9% in the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock worth $98,603,000 after acquiring an additional 853,740 shares during the period. Vanguard Group Inc. raised its position in Zenas BioPharma by 25.0% in the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after acquiring an additional 290,307 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new stake in Zenas BioPharma in the fourth quarter worth about $5,950,000. Invesco Ltd. bought a new stake in Zenas BioPharma in the third quarter worth about $3,237,000. Finally, Goldman Sachs Group Inc. bought a new stake in Zenas BioPharma in the fourth quarter worth about $4,746,000.

Analyst Ratings Changes

ZBIO has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Morgan Stanley lifted their target price on shares of Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $44.29.

Insider Activity at Zenas BioPharma

In other news, Director Fairmount Funds Management Llc acquired 150,000 shares of Zenas BioPharma stock in a transaction that occurred on Tuesday, March 31st. The stock was bought at an average price of $20.00 per share, with a total value of $3,000,000.00. Following the completion of the purchase, the director owned 2,359,025 shares in the company, valued at approximately $47,180,500. The trade was a 6.79% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Hongbo Lu acquired 3,768 shares of Zenas BioPharma stock in a transaction that occurred on Tuesday, March 31st. The shares were purchased at an average cost of $18.63 per share, with a total value of $70,197.84. Following the purchase, the director owned 426,736 shares of the company’s stock, valued at $7,950,091.68. This represents a 0.89% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 273,768 shares of company stock valued at $5,150,198. Corporate insiders own 22.00% of the company’s stock.

Zenas BioPharma Price Performance

ZBIO opened at $19.80 on Friday. The firm has a 50-day moving average price of $19.44 and a 200-day moving average price of $24.67. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -2.34 and a beta of -0.71. Zenas BioPharma, Inc. has a twelve month low of $8.91 and a twelve month high of $44.60. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same quarter in the previous year, the firm posted ($0.80) EPS. Equities analysts expect that Zenas BioPharma, Inc. will post -4.47 EPS for the current year.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.